The growth of the hospital acquired infection control market can largely be attributed to factors such as the high incidence of hospital-acquired infections, the increasing number of surgical procedures, the growing geriatric population and the increasing incidence of chronic diseases, technological advancements in sterilization equipment, and the growing awareness of environmental & personal hygiene due to COVID-19.
The increasing use of E-beam sterilization, reintroduction of ethylene oxide sterilization, and the growing healthcare industry and outsourcing of operation to emerging countries are expected to offer high-growth opportunities for market players during the forecast period.
Currently, with the surge in COVID-19 cases, there is an increasing focus on personal hygiene along with the increasing production of medical nonwovens and single-use products such as face masks and gloves. This is further expected to drive the growth of the hospital acquired infection control market in the coming years. On the other hand, concerns regarding the safety of reprocessed instruments are expected to limit market growth to some extent in the coming years.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=204343466
With the COVID-19 outbreak, there has been an unprecedented global demand for advanced healthcare facilities, services, and infrastructure to treat infected patients. With the considerable rise in the cases of COVID-19 across the globe, the number of patient admissions in hospitals has increased significantly, leading to an increase in the demand for disinfection and sterilization measures.
The increasing number of temporary hospitals, the growing need for remote care, and the rising influx of COVID-19 patients have resulted in the expansion of healthcare infrastructure and driven the demand for efficient hospital acquired infection control products and services.
Healthcare providers reprocess reusable medical devices to save money and reduce waste. Examples of reusable medical devices include surgical forceps, endoscopes, and stethoscopes. However, there are concerns about the safety and performance of reprocessed devices. Inadequate cleaning and sterilization of instruments can result in the retention of blood, tissue, and other biological debris in reusable devices, which increases the risk of surgical-site infections (SSIs) in patients.
The debris can allow microbes to survive the subsequent disinfection or sterilization process, which could then lead to HAIs. Inadequate reprocessing can also result in other adverse patient outcomes, such as tissue irritation from residual reprocessing materials such as chemical disinfectants. These factors are limiting the acceptance of reprocessing among hospital administrators and physicians.
However, with the growing number of COVID-19 cases worldwide, the adoption of EtO has increased to sterilize protective gear and single-use instruments before their initial use. This sterilization technology plays a vital role in enabling the sterilization of critical medical products and devices before reaching patients. According to the FDA, more than 20 billion devices sold in the US every year are sterilized with EtO, accounting for approximately 50% of the devices that require sterilization.
Market growth in this region is characterized by the growing demand for and adoption of sterilization and disinfection products along with services as a result of the rising focus on healthy lifestyles and disease prevention among consumers. The surge in the geriatric population in the coming years and the subsequent increase in the prevalence of chronic diseases, the need for hospital acquired infection control to minimize the prevalence of HAIs, and implementation of favorable government initiatives and stringent regulations on sterilization and disinfection are also propelling the hospital acquired infection market in the region.
The prominent players in Hospital Acquired Infection Control Market are STERIS plc (US), Sotera Health Company (US), Getinge AB (Sweden), Advanced Sterilization Products (ASP) (US), Ecolab Inc. (US), 3M Company (US), MATACHANA GROUP (Spain), MMM Group (Germany), Belimed AG (Switzerland), Reckitt Benckiser (UK), Metrex Research LLC (UK), Miele Group (Germany), Pal International (UK), MELAG Medizintechnik GmbH & Co. KG (Germany), Contec, Inc. (US), MEDALKAN (Greece), Systec GmbH (Germany), C.B.M. S.r.l. Medical Equipment (Italy), Continental Equipment Company (US), and BGS Beta-Gamma-Service GmbH & Co. KG (Germany).
No CommentsLeave a comment Cancel